The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Risk of Alzheimer's disease and duration of NSAID use
Open accessAbstract
In a longitudinal study of 1,686 participants in the Baltimore Longitudinal Study of Aging, we examined whether the risk of Alzheimer's disease (AD) was reduced among reported users of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, we examined use of acetaminophen, a pain-relief medication with little or no anti-inflammatory activity, to assess the specificity of the association between AD risk and self-reported medications. Information on use of medications was collected during each biennial examination between 1980 and 1995. The relative risk (RR) for AD decreased with increasing duration of NSAID use. Among those with 2 or more years of reported NSAID use, the RR was 0.40 (95% confidence interval [CI]: 0.19-0.84) compared with 0.65 (95% CI: 0.33-1.29) for those with less than 2 years of NSAID use. The overall RR for AD among aspirin users was 0.74 (95% CI: 0.46-1.18), and no trend of decreasing risk of AD was observed with increasing duration of aspirin use. No association was found between AD risk and use of acetaminophen (RR = 1.35; 95% CI: 0.79-2.30), and there was no trend of decreasing risk with increasing duration of use. These findings are consistent with evidence from cross-sectional studies indicating protection against AD risk among NSAID users and with evidence suggesting that one stage of the pathophysiology leading to AD is characterized by an inflammatory process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recognition that a robust inflammatory response contributes to AD also fuelled the discovery that long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk for AD, delayed disease onset, and slowed cognitive decline (McGeer et al., 1996;Stewart et al., 1997;in t' in t'Veld et al., 2001).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as Stewart et al., 1997
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Bayes Estimates for the Linear Model
Lindley, D. V., & Smith, A. F. M. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00885.x · Cited by 2,025
Normal Human Aging: The Baltimore Longitudinal Study on Aging
Shock, N. W., Greulich, R. C., Costa, P. T., Andres, R., Lakatta, E. G., Arenberg, D., & Tobin, J. D. (1984) · University Libraries (University of Maryland) · doi:10.13016/sclw-iccq · Cited by 757
Inverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
Activation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383
Stremmel, W., Strohmeyer, G. W., Borchard, F., Kochwa, S., & Berk, P. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.4 · Cited by 350
A Population-Based Study of the Risk of Recurrence of Birth Defects
Lie, R. T., Wilcox, A. J., & Skjærven, R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407073310101 · Cited by 164
Cohler, B. J., ROBBINS, D. M., Hartman, C. R., Shader, R. I., Grunebaum, H. U., Gallant, D. H., & Weiss, J. L. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90017-5 · Cited by 132
The need for multiple time points in aging studies
Coleman, P. A., Finch, C. E., & Joseph, J. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90055-5 · Cited by 66
Research works printed but not linked: 16
- Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481-495.
- Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study. Acta Neuropathol (Berl) 1982;57:239-252.
- Anonymous. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
- Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
- Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
- Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
- Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
- Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
- Morris JC, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
- Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
- Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
- Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence using the New Adult Reading Test. Cortex 1978;14:234-244.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
- Checkoway H Pearce NE Crawford-Brown DJ. Research methods in occupational epidemiology monographs in epidemiology and biostatistics vol 13. New York: Oxford University Press 1989:153-155.
- Aspirin Myocardial Infarction Study Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
- Paulas HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WN Harris ED Ruddy S Sledge CB eds. A textbook of rheumatology. Philadelphia: WB Saunders 1989.
Cited by
Sorted by citations
Items 201–300 of 1,000
Mental health and periodontal and peri‐implant diseases
Ball, J., & Darby, I. B. (2022) · Periodontology 2000 · doi:10.1111/prd.12452 · Cited by 187
Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease
Hanzel, C. E., Binette, A. P., Pimentel, L. S. B., Iulita, M. F., Allard, S. T. M., Ducatenzeiler, A., Carmo, S. D., & Cuello, A. C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.026 · Cited by 164
The role of APOE on lipid homeostasis and inflammation in normal brains
Rebeck, G. W. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075408 · Cited by 160
Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., Brooks, W. S., & Halliday, G. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1586 · Cited by 161
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models
Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., & Andreasson, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77487 · Cited by 161
Prostaglandin D2 mediates neuronal protection via the DP1 receptor
Liang, X., Wu, L., Hand, T. A., & Andreasson, K. I. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02870.x · Cited by 159
Neuroinflammation, gut microbiome, and Alzheimer's disease
Lin, L., Zheng, L. J., & Zhang, L. J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0983-2 · Cited by 147
Dementia Prevention: Methodological Explanations for Inconsistent Results
Coley, N., Andrieu, S., Gardette, V., Guyonnet, S., Sanz, C., Vellas, B. J., & Grand, A. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn010 · Cited by 162
Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D. W., Trojanowski, J. Q., Lee, V. M. ‐., & Praticò, D. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63269-5 · Cited by 157
Versijpt, J. J., Dumont, F., van Laere, K. J., Decoo, D., Santens, P., Audenaert, K., Achten, E., Slegers, G., Dierckx, R., & Korf, J. (2003) · European Neurology · doi:10.1159/000070857 · Cited by 152
Stem Cell-Derived Exosomes: a New Strategy of Neurodegenerative Disease Treatment
Hosseini, N. F., Sheykhhasan, M., Asl, S. S., & Najafi, R. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02324-x · Cited by 155
Aïd, S., Langenbach, R. I., & Bosetti, F. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-17 · Cited by 151
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease
Ferretti, M. T., Bruno, M. A., Ducatenzeiler, A., Klein, W. L., & Cuello, A. C. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.007 · Cited by 151
Mhatre, M., Floyd, R. A., & Hensley, K. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6206 · Cited by 148
Lipoxins: endogenous regulators of inflammation
McMahon, B. A., & Godson, C. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00224.2003 · Cited by 148
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Cardioprotective and neuroprotective roles of oleuropein in olive
Omar, S. H. (2010) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2010.05.005 · Cited by 147
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
AD Collaborative Group (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70293-4 · Cited by 149
Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease
Moore, A. H., & O’Banion, M. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00162-x · Cited by 150
Presenilin function and γ‐secretase activity
Brunkan, A. L., & Goate, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03099.x · Cited by 149
Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer’s disease
Arosio, B., Trabattoni, D., Galimberti, L., Bucciarelli, P., Fasano, F. R., Calabresi, C., Cazzullo, C. L., Vergani, C., Annoni, G., & Clerici, M. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.10.009 · Cited by 145
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H. S., West, C. R., Robbins, J. L., & Niculescu, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 144
Heneka, M. T., Gavrilyuk, V., Landreth, G. E., O’Banion, M. K., Weinberg, G. L., & Feinstein, D. L. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01694.x · Cited by 144
Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease
Doraiswamy, P. M. (2002) · CNS Drugs · doi:10.2165/00023210-200216120-00003 · Cited by 142
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 141
Alzheimer’s disease: Insights from epidemiology
McDowell, I. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351474 · Cited by 140
The effects of a novel NSAID on chronic neuroinflammation are age dependent☆
Hauss‐Wegrzyniak, B., Vraniak, P., & Wenk, G. L. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00028-7 · Cited by 141
Schachter, A. S., & Davis, K. L. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.2/asschachter · Cited by 153
Lipopolysaccharide enhances synthesis of brain-derived neurotrophic factor in cultured rat microglia
Miwa, T., Furukawa, S., Nakajima, K., Furukawa, Y., & Kohsaka, S. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19971215)50:6 · Cited by 181
Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease
Zana, M., Janka, Z., & Kalman, J. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.008 · Cited by 140
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET
Venneti, S., Lopresti, B. J., Wang, G., Hamilton, R. L., Mathis, C. A., Klunk, W. E., Apte, U. M., & Wiley, C. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.005 · Cited by 138
Glial cell dysregulation: a new perspective on Alzheimer disease
Rommy von Bernhardi, M. (2007) · Neurotoxicity Research · doi:10.1007/bf03033906 · Cited by 141
Periodontal disease, tooth loss and dementia: Is there a link? A systematic review
Tonsekar, P., Jiang, S. S., & Yue, G. (2017) · Gerodontology · doi:10.1111/ger.12261 · Cited by 148
Fu, W., Wang, X., & Ip, N. Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00402 · Cited by 138
Estrogen Action in Neuroprotection and Brain Inflammation
Pozzi, S., Benedusi, V., Maggi, A. C., & Vegeto, E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.035 · Cited by 137
Selim, S., Albqmi, M., Al-Sanea, M. M., Alnusaire, T. S., Almuhayawi, M. S., AbdElgawad, H., Jaouni, S. K. A., Elkelish, A., Hussein, S., Warrad, M., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1008349 · Cited by 143
Causes of Alzheimer's disease.
Muñoz, D. G., & Feldman, H. (2000) · PubMed Central · Cited by 136
Xiang, Z., Ho, L., Yemul, S., Zhao, Z., Pompl, P. N., Kelley, K. A., Dang, A., Qing, W., Teplow, D. B., & Pasinetti, G. M. (2002) · Gene Expression · doi:10.3727/000000002783992352 · Cited by 132
Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease
Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.006 · Cited by 134
Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent
Montine, T. J., Milatović, D., Gupta, R. C., Vályi-Nagy, T., Morrow, J. D., & BREYER, R. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01157.x · Cited by 133
Melnikova, T., Savonenko, A. V., Wang, Q., Liang, X., Hand, T. A., Wu, L., Kaufmann, W. E., Vehmas, A. K., & Andreasson, K. I. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.001 · Cited by 134
Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
Wolfe, M. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004897 · Cited by 135
NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models
COLE, G. M., MORIHARA, T., LIM, G. P., YANG, F., BEGUM, A., & FRAUTSCHY, S. A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.005 · Cited by 129
Targeting monocyte chemoattractant protein-1 signalling in disease
Dawson, J., Miltz, W., Mir, A. K., & Wießner, C. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.1.35 · Cited by 132
Gould, H. J., England, J. D., Soignier, R. D., Nolan, P., Minor, L. D., Liu, Z. P., Levinson, S. R., & Paúl, D. (2004) · Journal of Pain · doi:10.1016/j.jpain.2004.04.005 · Cited by 132
Inflammation, Apoptosis, and Alzheimer's Disease
Bamberger, M. E., & Landreth, G. E. (2002) · The Neuroscientist · doi:10.1177/1073858402008003013 · Cited by 129
Anti-inflammatories in Alzheimer’s disease—potential therapy or spurious correlate?
Rivers-Auty, J., Mather, A. E., Peters, R., Lawrence, C. B., & Brough, D. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa109 · Cited by 130
Ryu, J. K., Franciosi, S., Sattayaprasert, P., Kim, S. U., & McLarnon, J. G. (2004) · Glia · doi:10.1002/glia.20051 · Cited by 133
Dementia Care in 9 OECD Countries
Moïse, P., Schwarzinger, M., & Um, M. Y. (2004) · OECD health working papers · doi:10.1787/485700737071 · Cited by 131
Shadfar, S., Hwang, C. J., Lim, M., Choi, D., & Hong, J. T. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0648-x · Cited by 136
Gan, L., Ye, S., Chu, A., Anton, K., Yi, S.-L., Vincent, V. A. M., von Schack, D., Chin, D. J., Murray, J. C., Lohr, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306183200 · Cited by 130
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Will a Healthy Lifestyle Help Prevent Alzheimer's Disease?
Pope, S. K., Shue, V. M., & Beck, C. K. (2003) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.24.100901.141015 · Cited by 132
Treatment Strategies Targeting Amyloid -ProteinPreprint
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 131
Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice
López‐González, I., Schlüter, A., Aso, E., Garcia‐Esparcia, P., Ansoleaga, B., Llorens, F., Carmona, M., Moreno, J. R., Fuso, A., Portero‐Otín, M., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000176 · Cited by 128
Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. (2010) · Cited by 125
Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia
de Craen, A. J. M. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi029 · Cited by 124
Casamenti, F., Prosperi, C., Scali, C., Giovannelli, L., Colivicchi, M. A., Faussone‐Pellegrini, M. S., & Pepeu, G. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00680-0 · Cited by 122
Nonsteroidal anti‐inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease
Côté, S., Carmichael, P., Verreault, R., Lindsay, J., Lefèbvre, J., & Laurin, D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.03.012 · Cited by 126
Inflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 129
Fiebich, B. L., Schleicher, S., Spleiss, O., Czygan, M., & Hüll, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00652.x · Cited by 122
Does NSAID use modify cognitive trajectories in the elderly?
Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C. M., Lyketsos, C. G., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000265223.25679.2a · Cited by 123
Szekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121
Self-citationVarvel, N. H., Bhaskar, K., Kounnas, M. Z., Wagner, S. L., Yang, Y., Lamb, B. T., & Herrup, K. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39716 · Cited by 122
Ano, Y., Ozawa, M., Kutsukake, T., Sugiyama, S., Uchida, K., Yoshida, A., & Nakayama, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118512 · Cited by 121
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
Liang, X., Wang, Q., Shi, J., Lokteva, L. A., BREYER, R. M., Montine, T. J., & Andreasson, K. I. (2008) · Annals of Neurology · doi:10.1002/ana.21437 · Cited by 120
Kopeć, W., Telenius, J. M., & Khandelia, H. (2013) · FEBS Journal · doi:10.1111/febs.12286 · Cited by 118
Murphy, G. M., Yang, L., & Cordell, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.20967 · Cited by 118
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A., & Bennett, D. A. (2008) · Neurology · doi:10.1212/01.wnl.0000313813.48505.86 · Cited by 116
Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease
Wilkinson, B. L., Cramer, P. E., Varvel, N. H., Reed-Geaghan, E. G., Jiang, Q., Szabo, A., Herrup, K., Lamb, B. T., & Landreth, G. E. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.06.014 · Cited by 118
McGeer, P. L. (2000) · Drugs & Aging · doi:10.2165/00002512-200017010-00001 · Cited by 115
Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease
Uddin, M. S., Kabir, M. T., Mamun, A. A., Barreto, G. E., Rashid, M., Perveen, A., & Ashraf, G. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106479 · Cited by 121
Feinstein, D. L. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503763816481 · Cited by 116
Rosenberger, T., Villacreses, N., Hovda, J., Bosetti, F., Weerasinghe, G. R., Wine, R. N., Harry, G., & Rapoport, S. I. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02246.x · Cited by 123
Ferretti, M. T., Allard, S., Partridge, V., Ducatenzeiler, A., & Cuello, A. C. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-62 · Cited by 120
Dodel, R. C., Du, Y., Bales, K. R., Gao, F., & Paul, S. M. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731453.x · Cited by 114
Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease
Montine, T. J., & Morrow, J. D. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62347-4 · Cited by 118
Agdeppa, E. D. (2003) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2003.09.010 · Cited by 113
Simard, A. R., & Rivest, S. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001809 · Cited by 113
Alzheimer?s associated inflammation, potential drug targets and future therapies
Stuchbury, G., & M�nch, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0188-x · Cited by 113
Down Syndrome: Advances in Molecular Biology and the Neurosciences
Capone, G. T. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00007 · Cited by 110
Wotton, C. J., & Goldacre, M. J. (2017) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2016-207809 · Cited by 109
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Reconsider Alzheimer's disease by the ‘calpain–cathepsin hypothesis’—A perspective review
Yamashima, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.004 · Cited by 109
Xia, Y., Xiao, Y., Wang, Z.-H., Liu, X., Alam, A. M., Haran, J. P., McCormick, B. A., Shu, X., Wang, X., & Ye, K. (2023) · Nature Communications · doi:10.1038/s41467-023-41283-w · Cited by 108
Bezzi, P., Domercq, M., Vesce, S., & Volterra, A. (2001) · Progress in brain research · doi:10.1016/s0079-6123(01)32081-2 · Cited by 108
Alzheimer disease: protective factors
Nourhashémi, F., Guyonnet, S., Andrieu, S., Ghisolfi, A., Ousset, P., Grandjean, H., Grand, A., Pous, J., Vellas, B. J., & Albaréde, J. L. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.643s · Cited by 111
Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease
Yermakova, A. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00303-7 · Cited by 109
Kukull, W. A., & Bowen, J. D. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00010-x · Cited by 110
Xiang, Z. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00282-2 · Cited by 107
Mitochondrial Dynamics in Alzheimerʼs Disease
Bonda, D., Wang, X., Perry, G. L., Smith, M. A., & Zhu, X. (2010) · Drugs & Aging · doi:10.2165/11532140-000000000-00000 · Cited by 106
Nilsson, S. E., Johansson, B., Takkinen, S., Zarit, S., McClearn, G., Melander, A., & Berg, S. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0618-y · Cited by 104
The “Aspirin” of the New Millennium: Cyclooxygenase-2 Inhibitors
Buttar, N. S., & Wang, K. K. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.10.1027 · Cited by 105
Hydroxynonenal, toxic carbonyls, and Alzheimer disease
Liu, Q., Raina, A. K., Smith, M. A., Sayre, L. M., & Perry, G. L. (2003) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(03)00025-6 · Cited by 104
Neuroinflammation in Alzheimer’s Disease: from Pathogenesis to a Therapeutic Target
Pimplikar, S. W. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0032-5 · Cited by 106
Head, E., Azizeh, B. Y., Lott, I. T., Tenner, A. J., Cotman, C. W., & Cribbs, D. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0380 · Cited by 103
Dementia and its implications for public health.
Chapman, D. P., Williams, S. M., Strine, T. W., Anda, R. F., & Moore, M. J. (2006) · Europe PMC (PubMed Central) · Cited by 103
Dietary links to Alzheimer’s disease
Grant, W. B. (1997) · Cited by 104
Metadata
- Authors
- Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Neurology
- Published
- 1997-03
- Volume
- 48
- Issue
- 3
- Pages
- 626-632
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2163110760
- Cited by
- 1,132
- References
- 16
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 13 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 21 · 2017: 24 · 2016: 28 · 2015: 29 · 2014: 32 · 2013: 24 · 2012: 31
- FWCI
- 42.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- American Academy of Neurology
- National Institutes of Health
- National Institute on Aging (R01AG008325, R01-AG08325)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- Alzheimer's disease, nonsteroidal anti-inflammatory drugs, aspirin, paracetamol, medication use, neuroprotection, neuroinflammation
- MeSH terms
- Acetaminophen, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Confidence Intervals, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
